Baxter beats Wall Street projections but gets FDA questions on new treatment

It was one of those days for Baxter International ($BAX). It reported improved earnings but also learned the FDA wants more data on the immune deficiency drug it is developing with Halozyme Therapeutics.

Excluding one-time items, the drug company netted $569 million, or $1.01, beating by one cent what analysts had expected, Reuters reports. It also announced it will build a $1 billion plasma plant in Georgia.

The company says it is talking with the FDA about the new treatment to see what more is needed.

- check out Reuters' story